<SEC-DOCUMENT>0001213900-24-085933.txt : 20241007
<SEC-HEADER>0001213900-24-085933.hdr.sgml : 20241007
<ACCEPTANCE-DATETIME>20241007164509
ACCESSION NUMBER:		0001213900-24-085933
CONFORMED SUBMISSION TYPE:	S-3
PUBLIC DOCUMENT COUNT:		7
FILED AS OF DATE:		20241007
DATE AS OF CHANGE:		20241007

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Pasithea Therapeutics Corp.
		CENTRAL INDEX KEY:			0001841330
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				851591963
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-282532
		FILM NUMBER:		241358308

	BUSINESS ADDRESS:	
		STREET 1:		2110 NARCISSUS CT
		CITY:			VENICE
		STATE:			CA
		ZIP:			90291
		BUSINESS PHONE:		8184226172

	MAIL ADDRESS:	
		STREET 1:		2110 NARCISSUS CT
		CITY:			VENICE
		STATE:			CA
		ZIP:			90291
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3
<SEQUENCE>1
<FILENAME>ea0216529-s3_pasithea.htm
<DESCRIPTION>REGISTRATION STATEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>As filed with the Securities and Exchange Commission
on October 7, 2024</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No. 333- </B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>FORM S-3</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION STATEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE SECURITIES ACT OF 1933</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 100%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 12pt"><B>PASITHEA THERAPEUTICS CORP.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">(Exact name of registrant as specified in its charter)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>85-1591963</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">incorporation or organization)</P></TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(I.R.S. Employer</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Identification Number)</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>1111 Lincoln Road, Suite 500</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Miami Beach, Florida 33139</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>(786) 977-3380 </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(<I>Address, including zip code, and telephone
number,</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>including area code, of registrant&rsquo;s principal
executive offices</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Tiago Reis Marques</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Chief Executive Officer </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>1111 Lincoln Road, Suite 500</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Miami Beach, Florida 33139</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>(786) 977-3380 </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(<I>Name, address, including zip code, and telephone
number,</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>including area code, of agent for service</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Copies of all communications, including communications
sent to the agent for service, to:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>James O&rsquo;Grady, Esq.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Lowenstein Sandler LLP</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>1251 Avenue of the Americas</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>New York, New York 10020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Telephone: (212) 262-6700</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Approximate date of commencement of proposed
sale to the public</B>: From time to time after this Registration Statement becomes effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the only securities being registered on this
Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box: <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any of the securities being registered on this
Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered
only in connection with dividend or interest reinvestment plans, check the following box: <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form is filed to register additional securities
for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form is a post-effective amendment filed
pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of
the earlier effective registration statement for the same offering. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form is a registration statement pursuant
to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant
to Rule 462(e) under the Securities Act, check the following box. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form is a post-effective amendment to
a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities
pursuant to Rule 413(b) under the Securities Act, check the following box. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company.
See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting company,&rdquo;
and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%; text-align: justify"><FONT STYLE="font-size: 10pt">Large accelerated filer</FONT></TD>
    <TD STYLE="width: 30%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="width: 20%; text-align: justify"><FONT STYLE="font-size: 10pt">Accelerated filer</FONT></TD>
    <TD STYLE="width: 30%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Non-accelerated filer</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Smaller reporting company</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Emerging growth company</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The Registrant hereby amends this Registration
Statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which
specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities
Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to
said Section 8(a), may determine.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Red"><B>The information in
this preliminary prospectus is not complete and may be changed. The Selling Stockholders may not resell these securities until the registration
statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities,
nor is it a solicitation of offers to buy these securities, in any state where the offer or sale is not permitted.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-size: 10pt; color: Red"><B>PRELIMINARY PROSPECTUS</B></FONT></TD>
    <TD STYLE="width: 35%; text-align: center"><FONT STYLE="font-size: 10pt; color: Red"><B>SUBJECT TO COMPLETION</B></FONT></TD>
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-size: 10pt; color: Red"><B>DATED OCTOBER 7, 2024</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>3,743,905 Shares of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Issuable Upon Exercise of Outstanding Warrants</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus relates to
the resale of up to 3,743,905 shares of Pasithea Therapeutics Corp. (the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;our&rdquo; or
&ldquo;us&rdquo;) common stock, par value $0.0001 per share, by the Selling Stockholders listed in this prospectus (the &ldquo;Selling
Stockholders&rdquo;). The shares of common stock registered for resale pursuant to this prospectus consist of (i) 1,219,513 shares of
common stock (the &ldquo;Pre-Funded Warrant Shares&rdquo;) issuable upon the exercise of pre-funded warrants (the &ldquo;Pre-Funded Warrants&rdquo;),
(ii) 1,219,513 shares of common stock (the &ldquo;Series A Warrant Shares&rdquo;) issuable upon the exercise of Series A warrants (the
&ldquo;Series A Warrants&rdquo;), (iii) 1,219,513 shares of common stock (the &ldquo;Series B Warrant Shares&rdquo;) issuable upon the
exercise of Series B warrants (the &ldquo;Series B Warrants&rdquo;), and (iv) 85,366 shares of common stock (the &ldquo;Placement Agent
Warrant Shares&rdquo; and together with the Pre-Funded Warrant Shares, Series A Warrant Shares and Series B Warrant Shares, the &ldquo;Warrant
Shares&rdquo;) issuable upon the exercise of certain warrants issued to our placement agent (the &ldquo;Placement Agent Warrants&rdquo;
and together with the Pre-Funded Warrants, Series A Warrants and Series B Warrants, the &ldquo;Warrants&rdquo;). The Warrants were issued
to the Selling Stockholders in a private placement offering (the &ldquo;Private Placement&rdquo;) which closed on September 30, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For additional information
about the Private Placement, see &ldquo;<I>Private Placement</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Pre-Funded Warrants have
an exercise price of $0.001, are immediately exercisable and expire when exercised in full. The Series A Warrants and the Series B Warrants
have an exercise price of $3.85 per share. The Series A Warrants are immediately exercisable until the five (5) year anniversary of the
date of issuance. The Series B Warrants are immediately exercisable until the eighteen (18) month anniversary of the date of issuance.
The Placement Agent Warrants have substantially the same terms as the Series A Warrants, except that the Placement Agent Warrants have
an exercise price of $5.125.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Selling Stockholders may,
from time to time, sell, transfer, assign or otherwise dispose of any or all of their shares of common stock or interests in their shares of common
stock on any stock exchange, market or trading facility on which the shares of common stock are traded or in private transactions. These
dispositions may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price,
at varying prices determined at the time of sale, or at negotiated prices. See &ldquo;<I>Plan of Distribution</I>&rdquo; in this prospectus
for more information. We will not receive any proceeds from the resale or other disposition of the shares of common stock by the Selling
Stockholders. However, we will receive the proceeds of any cash exercise of the Warrants. See &ldquo;<I>Use of Proceeds</I>&rdquo; beginning
on page&nbsp;9&nbsp;and &ldquo;<I>Plan of Distribution</I>&rdquo; beginning on page&nbsp;10&nbsp;of this prospectus for more information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common stock and certain
of our outstanding warrants (the &ldquo;Public Warrants&rdquo;) are listed on the Nasdaq Capital Market (&ldquo;Nasdaq&rdquo;) under the
symbols &ldquo;KTTA&rdquo; and &ldquo;KTTAW,&rdquo; respectively. On October 4, 2024, the last reported sale price of our common stock
and Public Warrants as reported on Nasdaq was $5.34&nbsp;and $0.0361, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should read this prospectus,
together with additional information described under the headings &ldquo;<I>Incorporation of Certain Information by Reference</I>&rdquo;
and &ldquo;<I>Where You Can Find More Information</I>,&rdquo; carefully before you invest in any of our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>An investment in our securities
involves a high degree of risk. Before deciding whether to invest in our securities, you should consider carefully the risks and uncertainties
described in the section captioned &ldquo;<I>Risk Factors</I>&rdquo; contained in our Annual Report on Form 10-K for the fiscal year ended
December 31, 2023, filed with the Securities and Exchange Commission, or the SEC, on March 29, 2024 and our other filings we make with
the SEC from time to time, which are incorporated by reference herein in their entirety, together with other information in this prospectus
and the information incorporated by reference herein.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus
is truthful or complete. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The&nbsp;date&nbsp;of&nbsp;this&nbsp;prospectus&nbsp;is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;2024.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 92%"><A HREF="#ptc_001"><FONT STYLE="font-size: 10pt">PROSPECTUS SUMMARY</FONT></A></TD>
    <TD STYLE="width: 8%; text-align: center"><FONT STYLE="font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#b_001">THE OFFERING</A></TD>
    <TD STYLE="text-align: center">2</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#ptc_002"><FONT STYLE="font-size: 10pt">RISK FACTORS</FONT></A></TD>
    <TD STYLE="text-align: center">3</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#ptc_003"><FONT STYLE="font-size: 10pt">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="text-align: center">4</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#ptc_004"><FONT STYLE="font-size: 10pt">PRIVATE PLACEMENT</FONT></A></TD>
    <TD STYLE="text-align: center">6</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#ptc_005"><FONT STYLE="font-size: 10pt">SELLING STOCKHOLDERS</FONT></A></TD>
    <TD STYLE="text-align: center">7</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#ptc_006"><FONT STYLE="font-size: 10pt">USE OF PROCEEDS</FONT></A></TD>
    <TD STYLE="text-align: center">9</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#ptc_007"><FONT STYLE="font-size: 10pt">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD STYLE="text-align: center">10</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#ptc_008"><FONT STYLE="font-size: 10pt">DESCRIPTION OF SECURITIES</FONT></A></TD>
    <TD STYLE="text-align: center">12</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#ptc_009"><FONT STYLE="font-size: 10pt">LEGAL MATTERS</FONT></A></TD>
    <TD STYLE="text-align: center">15</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#ptc_010"><FONT STYLE="font-size: 10pt">EXPERTS</FONT></A></TD>
    <TD STYLE="text-align: center">15</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#ptc_011"><FONT STYLE="font-size: 10pt">WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
    <TD STYLE="text-align: center">15</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#ptc_012"><FONT STYLE="font-size: 10pt">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</FONT></A></TD>
    <TD STYLE="text-align: center">16</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="ptc_001"></A><B>PROSPECTUS SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>This summary highlights
information contained elsewhere in this prospectus and the documents incorporated by reference herein. This summary does not contain all
of the information that you should consider before deciding to invest in our securities. You should read this entire prospectus carefully,
including the section entitled &ldquo;Risk Factors&rdquo; beginning on page 3, our consolidated financial statements and the related
notes and the other information incorporated by reference into this prospectus before making an investment decision.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>This prospectus and the
information incorporated by reference herein contain references to trademarks, service marks and trade names owned by us or other companies.
Solely for convenience, trademarks, service marks and trade names referred to in this prospectus and the information incorporated by reference
herein, including logos, artwork, and other visual displays, may appear without the &reg; or <SUP>&reg;</SUP> symbols, but such references
are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights
of the applicable licensor to these trademarks, service marks and trade names. We do not intend our use or display of other companies&rsquo;
trade names, service marks or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. Other
trademarks, trade names and service marks appearing in this prospectus and the documents incorporated by reference herein are the property
of their respective owners.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Corporate Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a clinical-stage biotechnology
company primarily focused on the discovery, research and development of innovative treatments for CNS disorders and other diseases, including
RASopathies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our primary operations,
the Therapeutics segment, are focused on developing our lead therapeutic candidate, PAS-004, a next-generation macrocyclic
mitogen-activated protein kinase, or MEK inhibitor that we believe may address the limitations and liabilities associated with
existing drugs with a similar mechanism of action. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and MEK 2 for potential
use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (&ldquo;NF1&rdquo;)- associated neurofibromas and
a number of oncology indications, among others that we acquired from AlloMek Therapeutics, LLC in October 2022. In December 2023,
the FDA cleared our IND for PAS-004 and we received a study may proceed letter from the FDA for our Phase 1 multicenter, open-label,
dose escalation trial of PAS-004 in patients with MAPK pathway-driven advanced tumors with a documented RAS, NF1 or RAF mutation or
patients who have failed BRAF/MEK inhibition. We are currently conducting the Phase 1 clinical trial at four clinical sites in the
United States and plan to open an additional three sites in Eastern Europe in the fourth quarter of 2024. Our clinical development
plan for PAS-004 is to begin a Phase 1 clinical trial in adult patients with NF1-associated plexiform and/or cutaneous neurofibromas followed by pediatric patients
and ultimately seek FDA marketing approval in these patient populations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, we have two
programs that are in the discovery stage, which we believe address limitations in the treatment paradigm of the indications we plan to
address with these programs, which are currently ALS for PAS-003 and schizophrenia for PAS-001. During the year ended December 31, 2023,
we determined to cease further development of our PAS-002 program for multiple sclerosis due to several factors including the significant
capital, resources and time required to develop the program, and the current and projected availability of effective treatment options
for MS patients, among others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were formed as a Delaware
corporation in May 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Pasithea&rdquo; and
our other common law trademarks, service marks or trade names appearing herein are the property of Pasithea Therapeutics Corp. We do not
intend the use or display of other companies&rsquo; trademarks and trade names to imply a relationship with, or endorsement or sponsorship
of us by, any other companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our mailing address is 1111
Lincoln Road, Suite 500, Miami Beach, FL 33139 and our telephone number is (702) 514-4174. Our website address is www.pasithea.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Information contained in,
or accessible through, our website does not constitute part of this prospectus or registration statement and inclusions of our website
address in this prospectus or registration statement are inactive textual references only. You should not rely on any such information
in making your decision whether to purchase our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="b_001"></A><B>THE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 23%"><FONT STYLE="font-size: 10pt"><B>Common Stock to be offered by the Selling Stockholders&nbsp;</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 75%; text-align: justify"><FONT STYLE="font-size: 10pt">Up to 3,743,905 shares of common stock, which are comprised of (i) 1,219,513 shares of common stock issuable upon exercise of the Pre-Funded Warrants, (ii) 1,219,513 shares of common stock issuable upon exercise of the Series A Warrants, (iii) &nbsp;1,219,513 shares of common stock issuable upon exercise of the Series B Warrants, and (iv) 85,366 shares of common stock issuable upon exercise of the Placement Agent Warrants. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Use of Proceeds</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We will not receive any proceeds from the shares of common stock offered by the Selling Stockholders pursuant to this prospectus. However, we will receive the proceeds of any cash exercise of the Warrants. We intend to use the net proceeds from any cash exercise of the Warrants for working capital and other general corporate purposes. Please see the section entitled see &ldquo;<I>Use of Proceeds</I>&rdquo; on page 9 of this prospectus for a more detailed discussion.&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>National Securities Exchange Listing</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Our common stock and our Public Warrants are currently listed on Nasdaq under the symbols &ldquo;KTTA&rdquo; and &ldquo;KTTAW,&rdquo; respectively. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Risk Factors</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">An investment in our securities involves a high degree of risk. Please see the section entitled &ldquo;<I>Risk Factors</I>&rdquo; beginning on page 3&nbsp;of this prospectus. In addition before deciding whether to invest in our securities, you should consider carefully the risks and uncertainties described in the section captioned &ldquo;<I>Risk Factors</I>&rdquo; contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the SEC on March 29, 2024, and other filings we make with the SEC from time to time, which are incorporated by reference herein in their entirety, together with other information in this prospectus and the information incorporated by reference herein.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="ptc_002"></A><B>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An investment in our securities
involves a high degree of risk. Before deciding whether to invest in our securities, you should consider carefully the risks and uncertainties
described in the section captioned &ldquo;<I>Risk Factors</I>&rdquo; contained in our Annual Report on Form 10-K for the fiscal year ended
December 31, 2023 filed with the SEC on March 29, 2024, and our other filings we make with the SEC from time to time, which are incorporated
by reference herein in their entirety, together with other information in this prospectus and the information incorporated by reference
herein. If any of these risks actually occurs, our business, financial condition, results of operations or cash flow could suffer materially.
In such an event, the trading price of our shares of common stock could decline, and you might lose all or part of your investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="ptc_003"></A><B>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt">Except for historical information,
this prospectus contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, (the
&ldquo;Securities Act&rdquo;) and Section 21E of the Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;). Forward-looking
statements include statements with respect to our beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates,
intentions and future performance, and involve known and unknown risks, uncertainties and other factors, which may be beyond our control,
and which may cause our actual results, performance or achievements to be materially different from future results, performance or achievements
expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could
be forward-looking statements. You can identify these forward-looking statements through our use of words such as &ldquo;may,&rdquo; &ldquo;can,&rdquo;
&ldquo;anticipate,&rdquo; &ldquo;assume,&rdquo; &ldquo;should,&rdquo; &ldquo;indicate,&rdquo; &ldquo;would,&rdquo; &ldquo;believe,&rdquo;
&ldquo;contemplate,&rdquo; &ldquo;expect,&rdquo; &ldquo;seek,&rdquo; &ldquo;estimate,&rdquo; &ldquo;continue,&rdquo; &ldquo;plan,&rdquo;
&ldquo;point to,&rdquo; &ldquo;project,&rdquo; &ldquo;predict,&rdquo; &ldquo;could,&rdquo; &ldquo;intend,&rdquo; &ldquo;target,&rdquo;
&ldquo;potential&rdquo; and other similar words and expressions of the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt">There are a number of important
factors that could cause the actual results to differ materially from those expressed in any forward-looking statement made by us. These
factors include, but are not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our lack of operating history;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the expectation that we will incur significant operating losses for the foreseeable future and will need significant additional capital;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our plans to develop and commercialize our product candidates involves a lengthy and expensive process, with an uncertain outcome;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the initiation, enrollment, timing, progress, results, and cost of our research and development programs and our current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the timing of interim data and final results from our clinical trials for PAS-004;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the potential safety and efficacy of our product candidates and the therapeutic implications of clinical and preclinical data;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the timing and focus of our future preclinical studies and clinical trials, and the reporting of data from those studies and trials;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the size of the market opportunity for our future product candidates, including our estimates of the number of patients who suffer from the diseases we are targeting;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the success of competing therapies that are or may become available;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the beneficial characteristics, safety, efficacy and therapeutic effects of our future product candidates;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to obtain and maintain regulatory approval of our future product candidates;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our plans relating to the further development of our future product candidates, including additional disease states or indications we may pursue;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">existing regulations and regulatory developments in the United States and other jurisdictions;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our dependence on third parties;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the need to hire additional personnel and our ability to attract and retain such personnel;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our plans and ability to obtain or protect intellectual property rights, including extensions of patent terms where available and our ability to avoid infringing the intellectual property rights of others;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">our financial performance and sustaining an active trading market for
our common stock and Public Warrants;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to restructure our operations to comply with any potential future changes in government regulation;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">disruptions to the development of our product candidates due to public health crises, such as epidemics and pandemics, including the COVID-19 global pandemic;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">the impact of global economic and market conditions and political developments
on our business, including, among others, rising inflation and capital market disruptions, economic sanctions, bank failures, regional
conflicts around the world, and economic slowdowns or recessions that may result from such developments which could harm our research
and development efforts as well as the value of our common stock and our ability to access capital markets;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">business interruptions resulting from geopolitical actions and global events, including political instability, natural disasters and events of terrorism and wars such as the war between Ukraine and Russia, and the corresponding tensions created from such conflict between Russia, the United States and countries in Europe as well as other countries such as China, and the conflict between Hamas and Israel;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our reliance on foreign contract research organizations (CROs) and contract manufacturing organizations (CMOs), including WuXi AppTec, that may be subject to U.S. legislation, including the proposed BIOSECURE bill, trade restrictions and other foreign regulatory requirements which could increase the cost or reduce the supply of material available to us, delay the procurement or supply of such material or have an adverse effect on our ability to secure significant commitments from governments to purchase our potential therapies; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">other factors discussed in our most recent Annual Report on Form 10-K.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing does not represent
an exhaustive list of matters that may be covered by the forward-looking statements contained herein, or those documents incorporated
by reference, or risk factors that we are faced with that may cause our actual results to differ from those anticipate in our forward-looking
statements. Please see &ldquo;<I>Risk Factors</I>&rdquo; for additional risks which could adversely impact our business and financial
performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All forward-looking statements
are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking
statements, which speak only as of the date of this prospectus, or the date of the document incorporated by reference into this prospectus.
We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether
as a result of new information, future events or otherwise. We have expressed our expectations, beliefs and projections in good faith,
and we believe they have a reasonable basis. However, we cannot assure you that our expectations, beliefs, or projections will result
or be achieved or accomplished.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="ptc_004"></A><B>PRIVATE PLACEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt">On September 26, 2024, we
entered into securities purchase agreement (the &ldquo;Purchase Agreement&rdquo;) with an institutional investor for the issuance and
sale in a private placement (the &ldquo;Private Placement&rdquo;) of (i) Pre-Funded Warrants to purchase up to 1,219,513 shares of common
stock, with an exercise price of $0.001 per share, (ii) Series A Warrants to purchase up to 1,219,513 shares of common stock, with an
exercise price of $3.85 per share, and (iii) Series B Warrants to purchase up to 1,219,513 shares of common stock with an exercise price
of $3.85 per share. The Pre-Funded Warrants are immediately exercisable and expire when exercised in full. The Series A Warrants are exercisable
immediately upon issuance and have a term of exercise equal to five (5) years from the date of issuance. The Series B Warrants are exercisable
immediately upon issuance and have a term of exercise equal to eighteen (18) months from the date of issuance. The combined purchase price
per Pre-Funded Warrant and accompanying Series A Warrant and Series B Warrant was $4.099. The Private Placement closed on September 30,
2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt">In connection with the Private
Placement, we entered into a registration rights agreement (the &ldquo;Registration Rights Agreement&rdquo;), dated as of September 26,
2024, with the investor, pursuant to which we agreed to prepare and file a registration statement registering the resale of the shares
of common stock underlying the Pre-Funded Warrants, Series A Warrants and Series B Warrants no later than fifteen (15) days after the
date of the Registration Rights Agreement, and to use our best efforts to have the registration statement declared effective as promptly
as practical thereafter, and in any event no later than forty-five (45) days following the date of the Registration Rights Agreement (or
ninety (90) days following the date of the Registration Rights Agreement in the event of a &ldquo;full review&rdquo; by the SEC). We have
filed the registration statement of which this prospectus forms a part pursuant to the Registration Rights Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt">H.C. Wainwright &amp; Co.,
LLC (the &ldquo;Placement Agent&rdquo;) served as our exclusive placement agent in connection with the Private Placement, pursuant to
that certain engagement letter, dated as of September 6, 2024, as amended on September 26, 2024, between us and the Placement Agent (the
&ldquo;Engagement Letter&rdquo;). Pursuant to the Engagement Letter, we paid the Placement Agent (i) a total cash fee equal to 7.0% of
the aggregate gross proceeds of the Private Placement, (ii) a management fee of 1.0% of the aggregate gross proceeds of the Private Placement
and (iii) a non-accountable expense allowance of $50,000. In addition, in connection with the Private Placement, we issued the Placement
Agent or its designees the Placement Agent Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="ptc_005"></A><B>SELLING STOCKHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt">This prospectus covers the
resale or other disposition by the Selling Stockholders identified in the table below of up to an aggregate 3,743,905<B>&nbsp;</B>shares
of our common stock issuable upon the exercise of the Warrants. The Selling Stockholders acquired their securities in the transactions
described above under the heading <I>&ldquo;Private Placement</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt">The Warrants held by the
Selling Stockholders contain limitations which prevent the holder from exercising such Warrants if such exercise would cause the Selling
Stockholder, together with certain related parties, to beneficially own a number of shares of common stock which would exceed 4.99% (or,
at the election of the holder, 9.99%) of our then outstanding shares of common stock following such exercise, excluding for purposes of
such determination, shares of common stock issuable upon exercise of the Warrants which have not been exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt">The table below sets forth,
as of October 1, 2024, the following information regarding the Selling Stockholders:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD><FONT STYLE="font-size: 10pt">the names of the Selling Stockholders;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD><FONT STYLE="font-size: 10pt">the number of shares of common stock owned by the Selling Stockholders prior to this offering, without regard to any beneficial ownership limitations contained in the Warrants;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD><FONT STYLE="font-size: 10pt">the number of shares of common stock to be offered by the Selling Stockholders in this offering;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the number of shares of common stock to be owned by the Selling Stockholders assuming the sale of all of the shares of common stock covered by this prospectus; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the percentage of our issued and outstanding shares of common stock to be owned by Selling Stockholders assuming the sale of all of the shares of common stock covered by this prospectus based on the number of shares of common stock issued and outstanding as of October 1, 2024.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt">Except as described above,
the number of shares of common stock beneficially owned by the Selling Stockholder has been determined in accordance with Rule 13d-3 under
the Exchange Act and includes, for such purpose, shares of common stock that the Selling Stockholder has the right to acquire within 60
days of October 1, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt">All information with
respect to the common stock ownership of the Selling Stockholders has been furnished by or on behalf of the Selling Stockholders. We
believe, based on information supplied by the Selling Stockholders, that except as may otherwise be indicated in the footnotes to
the table below, the Selling Stockholder has sole voting and dispositive power with respect to the shares of common stock reported
as beneficially owned by the Selling Stockholders. Because the Selling Stockholders identified in the table may sell some or all of
the shares of common stock beneficially owned by them and covered by this prospectus, and because there are currently no agreements,
arrangements or understandings with respect to the sale of any of the shares of common stock, no estimate can be given as to the
number of shares of common stock available for resale hereby that will be held by the Selling Stockholders upon termination of this
offering. In addition, the Selling Stockholders may have sold, assigned, transferred or otherwise disposed of, or may sell, transfer
or otherwise dispose of, at any time and from time to time, the shares of common stock they beneficially own in transactions exempt
from the registration requirements of the Securities Act after the date on which they provided the information set forth in the
table below. We have, therefore, assumed for the purposes of the following table, that the Selling Stockholders will sell all of the
shares of common stock owned beneficially by it that are covered by this prospectus, but will not sell any other shares of common
stock that they presently own. Except as set forth below, the Selling Stockholders have not held any position or office, or have
otherwise had a material relationship, with us or any of our subsidiaries within the past three years other than as a result of the
ownership of our shares of common stock or other securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">Name of Selling Stockholders</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Shares</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Owned</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>prior to</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Offering</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Shares</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Offered</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>by this</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Prospectus</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Shares</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Owned after</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Offering</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Percentage of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Shares</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Beneficially</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Owned after</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Offering (1)</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left">Armistice Capital, LLC (2)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">3,779,968</TD><TD STYLE="width: 1%; text-align: left"></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">3,658,539</TD><TD STYLE="width: 1%; text-align: left">(3)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">121,429</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">2.6</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Charles Worthman (4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">854</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">854</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Craig Schwabe (4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,881</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,881</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Michael Vasinkevich (4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">54,741</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">54,741</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Noam Rubinstein (4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,890</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,890</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Percentages are based on 1,044,914 shares of common stock outstanding as of October 1, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The securities are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the &ldquo;Master Fund&rdquo;) and may be deemed to be beneficially owned by: (i) Armistice Capital, LLC (&ldquo;Armistice Capital&rdquo;), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital. The number of shares listed in the second and fourth columns are based on the number of shares of warrants held by the Master Fund, assuming exercise in full of the warrants without regard to any limitations on exercise, but the percentage set forth in the fifth column is limited by beneficial ownership blockers applicable to such warrants. The address of Armistice Capital Master Fund Ltd. is c/o Armistice Capital, LLC, 510 Madison Avenue, 7th Floor, New York, NY 10022.&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Contains (i) Pre-Funded Warrants to purchase up to 1,219,513 shares of common stock, subject to a beneficial ownership blocker of 9.99%, (ii) Series A Warrants to purchase up to 1,219,513 shares of common stock, subject to a beneficial ownership blocker of 4.99%, and (iii) Series B Warrants to purchase up to 1,219,513 shares of common stock, subject to a beneficial ownership blocker of 4.99%. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Each of the Selling Stockholders is affiliated with H.C. Wainwright &amp; Co., LLC, a registered broker dealer with a registered address of H.C. Wainwright &amp; Co., LLC, 430 Park Ave, 3rd Floor, New York, NY 10022, and has sole voting and dispositive power over the securities held. The Selling Stockholder acquired the Placement Agent Warrants in the ordinary course of business and, at the time the Placement Agent Warrants were acquired, the Selling Stockholder had no agreement or understanding, directly or indirectly, with any person to distribute such securities. H.C. Wainwright &amp; Co., LLC served as our exclusive placement agent in connection with the Private Placement, for which it received compensation.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="ptc_006"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
common stock to be offered and sold using this prospectus will be offered and sold by the Selling Stockholders named in this prospectus.
Accordingly, we will not receive any proceeds from any sale of shares of common stock in this offering. We will pay all of the fees and
expenses incurred by us in connection with this registration. However, we will receive the proceeds of any cash exercise of the Warrants.
We intend to use the net proceeds from any cash exercise of the Warrants for working capital and other general corporate purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="ptc_007"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PLAN
OF DISTRIBUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Selling Stockholder of the securities and any of their pledgees, donees, assignees, transferees and successors-in-interest may, from time to
time, sell any or all of their securities covered hereby on The Nasdaq Capital Market or any other stock exchange, market or trading
facility on which the securities are traded or in private transactions. These sales may be at fixed or negotiated prices. A Selling
Stockholder may use any one or more of the following methods when selling securities:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ordinary brokerage transactions
    and transactions in which the broker-dealer solicits purchasers;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">block trades in which the
    broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the block as principal to facilitate
    the transaction;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchases by a broker-dealer
    as principal and resale by the broker-dealer for its account;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an exchange distribution
    in accordance with the rules of the applicable exchange;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">privately negotiated transactions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">settlement of short sales;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in transactions through
    broker-dealers that agree with the Selling Stockholders to sell a specified number of such securities at a stipulated price per security;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">through the writing or
    settlement of options or other hedging transactions, whether through an options exchange or otherwise;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a combination of any such
    methods of sale; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any other method permitted
    pursuant to applicable law.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Selling Stockholders may also sell securities under Rule 144 or any other exemption from registration under the Securities Act, if available,
rather than under this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Broker-
dealers engaged by the Selling Stockholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive
commissions or discounts from the Selling Stockholders (or, if any broker-dealer acts as agent for the purchaser of securities, from
the purchaser) in amounts to be negotiated, but, except as set forth in a supplement to this Prospectus, in the case of an agency transaction
not in excess of a customary brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction a markup
or markdown in compliance with FINRA Rule 2121.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the sale of the securities or interests therein, the Selling Stockholders may enter into hedging transactions with broker-dealers
or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they
assume. The Selling Stockholders may also sell securities short and deliver these securities to close out their short positions, or loan
or pledge the securities to broker-dealers that in turn may sell these securities. The Selling Stockholders may also enter into option
or other transactions with broker-dealers or other financial institutions or create one or more derivative securities which require the
delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer
or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Selling Stockholders and any broker-dealers or agents that are involved in selling the securities may be deemed to be &ldquo;underwriters&rdquo;
within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers
or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts
under the Securities Act. Each Selling Stockholder has informed us that it does not have any written or oral agreement or understanding,
directly or indirectly, with any person to distribute the securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are required to pay certain fees and expenses incurred by us incident to the registration of the securities. We have agreed to indemnify
the Selling Stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
agreed to keep this prospectus effective until the earlier of (i) the date on which the securities may be resold by the Selling Stockholders
without registration and without regard to any volume or manner-of-sale limitations by reason of Rule 144, without the requirement for
us to be in compliance with the current public information under Rule 144 under the Securities Act or any other rule of similar effect
or (ii) all of the securities have been sold pursuant to this prospectus or Rule 144 under the Securities Act or any other rule of similar
effect. The resale securities will be sold only through registered or licensed brokers or dealers if required under applicable state
securities laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they have been registered
or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is
complied with.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously
engage in market making activities with respect to the common stock for the applicable restricted period, as defined in Regulation M,
prior to the commencement of the distribution. In addition, the Selling Stockholders will be subject to applicable provisions of the
Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the
common stock by the Selling Stockholders or any other person. We will make copies of this prospectus available to the Selling Stockholders
and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including
by compliance with Rule 172 under the Securities Act).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is quoted on Nasdaq under the symbol &ldquo;KTTA.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="ptc_008"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DESCRIPTION
OF SECURITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summary of the rights of our capital stock is not complete and is subject to and qualified in its entirety by reference to
our Second Amended and Restated Certificate of Incorporation, as amended (the &ldquo;Certificate of Incorporation&rdquo;) and Second
Amended and Restated Bylaws (the &ldquo;Bylaws&rdquo;)<I>, </I>copies of which are filed as exhibits to the registration statement of
which this prospectus forms a part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are authorized to issue an aggregate of 105,000,000 shares. The authorized capital stock is divided into 100,000,000 shares of common
stock having a par value of $0.0001 per share and 5,000,000 shares of preferred stock having a par value of $0.0001 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I>Common
Stock&#9;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
shares of our common stock are one and the same class, identical in all respects and have equal rights, powers and privileges.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting</I>.
Except as otherwise provided by law or by the resolution or resolutions providing for the issue of any series of preferred stock, the
holders of outstanding shares of common stock have the exclusive right to vote for the election and removal of directors and for all
other purposes. On each matter on which holders of common stock are entitled to vote, each outstanding share of such common stock is
entitled to one vote.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dividends</I>.
Subject to the rights of the holders of preferred stock, holders of shares of common stock are entitled to receive such dividends and
distributions and other distributions of our cash, stock or property when, as and if declared by our board of directors (the &ldquo;Board&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Liquidation</I>.
Subject to the rights of the holders of preferred stock, shares of common stock are entitled to receive our assets and funds available
for distribution in the event of any liquidation, dissolution or winding up of the affairs of us, whether voluntary or involuntary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Rights
and Preferences</I>. Holders of our common stock will have no preemptive, conversion or subscription rights, and there will be no redemption
or sinking funds provisions applicable to our common stock. The rights, preferences and privileges of the holders of our common stock
will be subject to, and may be adversely affected by, the rights of the holders of share of any series of our preferred stock that we
may designate and issue in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Preferred
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board has the authority, without further action by our stockholders, to issue up to 5,000,000 shares of preferred stock in one or more
classes or series. Our Board is able to determine, with respect to any series of preferred stock, the powers (including voting powers),
preferences and relative, participating, optional or other special rights, and the qualifications, limitations or restrictions thereof,
including, without limitation:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the designation
    of the series;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of shares of
    the series, which our Board may, except where otherwise provided in the preferred stock designation, increase (but not above the
    total number of authorized shares of the class) or decrease (but not below the number of shares then outstanding);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether dividends, if any,
    will be cumulative or non-cumulative and the dividend rate of the series;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the dates at which dividends,
    if any, will be payable;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the redemption or repurchase
    rights and price or prices, if any, for shares of the series;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the terms and amounts of
    any sinking fund provided for the purchase or redemption of shares of the series;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the amounts payable on,
    and the preferences, if any, of shares of the series in the event of any voluntary or involuntary liquidation, dissolution or winding-up
    of our affairs;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether the
    shares of the series will be convertible into shares of any other class or series, or any other security, of us or any other entity,
    and, if so, the specification of the other class or series or other security, the conversion price or prices or rate or rates, any
    rate adjustments, the date or dates as of which the shares will be convertible and all other terms and conditions upon which the
    conversion may be made;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions on the issuance
    of shares of the same series or of any other class or series;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the voting rights, if any,
    of the holders of the series; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any other powers, preferences
    and relative, participating, optional or other special rights of each series of preferred stock, and any qualifications, limitations
    or restrictions thereof, all as may be determined from time to time by our Board and stated in the resolution or resolutions providing
    for the issuance of such preferred stock.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
could issue a series of preferred stock that could, depending on the terms of the series, impede or discourage an acquisition attempt
or other transaction that some, or a majority, of the holders of our common stock might believe to be in their best interests or in which
the holders of our common stock might receive a premium over the market price of the shares of our common stock. Additionally, the issuance
of preferred stock may adversely affect the rights of holders of our common stock by restricting dividends on the common stock, diluting
the voting power of the common stock or subordinating the liquidation rights of the common stock. As a result of these or other factors,
the issuance of preferred stock could have an adverse impact on the market price of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Anti-Takeover
Effects of Delaware law and Our Certificate of Incorporation and Bylaws</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Incorporation, Bylaws and the Delaware General Corporation Law (the &ldquo;DGCL&rdquo;) contain provisions that are intended
to enhance the likelihood of continuity and stability in the composition of our Board. These provisions are intended to avoid costly
takeover battles, reduce our vulnerability to a hostile or abusive change of control and enhance the ability of our Board to maximize
stockholder value in connection with any unsolicited offer to acquire us. However, these provisions may have an anti-takeover effect
and may delay, deter or prevent a merger or acquisition of our company by means of a tender offer, a proxy contest or other takeover
attempt that a stockholder might consider in its best interest, including those attempts that might result in a premium over the prevailing
market price for the shares of common stock held by stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Section
203 of the Delaware General Corporation Law</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to Section 203 of the DGCL, which prohibits a Delaware corporation from engaging in any business combination with any interested
stockholder for a period of three years after the date that such stockholder became an interested stockholder, with the following exceptions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">before
    such date, the board of directors of the corporation approved either the business combination or the transaction that resulted in
    the stockholder becoming an interested stockholder;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon
    completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned
    at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining
    the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned (i) by
    persons who are directors and also officers and (ii) employee stock plans in which employee participants do not have the right to
    determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
    or after such date, the business combination is approved by the board of directors and authorized at an annual or special meeting
    of the stockholder, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock that
    is not owned by the interested stockholder.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, Section 203 defines business combination to include the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any merger or consolidation
    involving the corporation and the interested stockholder;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any sale, transfer, pledge
    or other disposition of 10% or more of the assets of the corporation involving the interested stockholder;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject to certain exceptions,
    any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any transaction involving
    the corporation that has the effect of increasing the proportionate share of the stock or any class or series of the corporation
    beneficially owned by the interested stockholder; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the receipt by the interested
    stockholder of the benefit of any loss, advances, guarantees, pledges or other financial benefits by or through the corporation.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, Section 203 defines an &ldquo;interested stockholder&rdquo; as an entity or person who, together with the person&rsquo;s affiliates
and associates, beneficially owns, or within three years prior to the time of determination of interested stockholder status did own,
15% or more of the outstanding voting stock of the corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Potential
Effects of Authorized but Unissued Stock</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to our Certificate of Incorporation, we have shares of common stock and preferred stock available for future issuance without stockholder
approval. We may utilize these additional shares for a variety of corporate purposes, including future public offerings to raise additional
capital, to facilitate corporate acquisitions or payment as a dividend on the capital stock.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
existence of unissued and unreserved common stock and preferred stock may enable our Board to issue shares to persons friendly to current
management or to issue preferred stock with terms that could render more difficult or discourage a third-party attempt to obtain control
of us by means of a merger, tender offer, proxy contest or otherwise, thereby protecting the continuity of our management. In addition,
our Board has the discretion to determine designations, rights, preferences, privileges and restrictions, including voting rights, dividend
rights, conversion rights, redemption privileges and liquidation preferences of each series of preferred stock, all to the fullest extent
permissible under the DGCL and subject to any limitations set forth in our Certificate of Incorporation. The purpose of authorizing our
Board to issue preferred stock and to determine the rights and preferences applicable to such preferred stock is to eliminate delays
associated with a stockholder vote on specific issuances. The issuance of preferred stock, while providing desirable flexibility in connection
with possible financings, acquisitions and other corporate purposes, could have the effect of making it more difficult for a third-party
to acquire, or could discourage a third-party from acquiring, a majority of our outstanding voting stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transfer
Agent and Registrar</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transfer agent and registrar for our common stock is VStock Transfer, LLC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>National
Securities Exchange Listing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is currently listed on Nasdaq under the symbol &ldquo;KTTA.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="ptc_009"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
validity of the shares of common stock offered hereby will be passed upon for us by Lowenstein Sandler LLP, New York, New York.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="ptc_010"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
audited annual consolidated financial statements of Pasithea Therapeutics Corp. incorporated by reference in this prospectus and
elsewhere in the registration statement have been incorporated by reference in reliance upon the report of Marcum LLP, independent
registered public accounting firm, which includes an explanatory paragraph as to the Company's ability to continue as a going
concern, upon the authority of said firm as experts in accounting and auditing. The 2023 and 2022 audited annual consolidated
financial statements of Pasithea Therapeutics Corp. as of and for the years ended December 31, 2023 and 2022, have been audited by
Marcum LLP, independent registered public accounting firm.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="ptc_011"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHERE
YOU CAN FIND MORE INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have filed with the SEC a registration statement on Form S-3 under the Securities Act with respect to the shares of common stock offered
by this prospectus. This prospectus, which is part of the registration statement, omits certain information, exhibits, schedules and
undertakings set forth in the registration statement. For further information pertaining to us and our securities, reference is made
to our SEC filings and the registration statement and the exhibits and schedules to the registration statement. Statements contained
in this prospectus as to the contents or provisions of any documents referred to in this prospectus are not necessarily complete, and
in each instance where a copy of the document has been filed as an exhibit to the registration statement, reference is made to the exhibit
for a more complete description of the matters involved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, registration statements and certain other filings made with the SEC electronically are publicly available through the SEC&rsquo;s
web site at http://www.sec.gov. The registration statement, including all exhibits and amendments to the registration statement, has
been filed electronically with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to the information and periodic reporting requirements of the Exchange Act, as amended, and, in accordance with such requirements,
will file periodic reports, proxy statements, and other information with the SEC. These periodic reports, proxy statements, and other
information will be available for inspection and copying at the web site of the SEC referred to above. We also maintain a website at
https://www.pasithea.com, at which you may access these materials free of charge as soon as reasonably practicable after they are electronically
filed with, or furnished to, the SEC. The information contained in, or that can be accessed through, our website is not part of, and
is not incorporated into, this prospectus. We have included our website address in this prospectus solely as an inactive textual reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="ptc_012"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INCORPORATION
OF CERTAIN INFORMATION BY REFERENCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC allows us to &ldquo;incorporate by reference&rdquo; information that we file with it into this prospectus, which means that we can
disclose important information to you by referring you to those documents. The information incorporated by reference is an important
part of this prospectus. The information incorporated by reference is considered to be a part of this prospectus, and information that
we file later with the SEC will automatically update and supersede information contained in this prospectus and any accompanying prospectus
supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
incorporate by reference the documents listed below that we have previously filed with the SEC:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1841330/000121390024027508/ea0200415-10k_pasithea.htm">March 29, 2024</A>;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    Quarterly Report on Form 10-Q for the quarters ended March 31, 2024 and June 30, 2024, as filed with the SEC on&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1841330/000121390024042981/ea0205253-10q_pasithea.htm">May 14, 2024</A>&nbsp;and <A HREF="http://www.sec.gov/Archives/edgar/data/1841330/000121390024068297/ea0210146-10q_pasithea.htm">August 13, 2024</A>, respectively;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    Current Reports on Form 8-K as filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1841330/000121390024000296/ea190803-8k_pasithea.htm">January 2, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1841330/000121390024004520/ea191820-8k_pasithea.htm">January 18, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1841330/000121390024043036/ea0205945-8k_pasithea.htm">May 14, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1841330/000121390024056205/ea0208474-8k_pasithea.htm">June 26, 2024</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1841330/000121390024083408/ea0215863-8k_pasithea.htm">September 30, 2024</A> (other than any portions thereof deemed furnished and not filed); and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    description of our common stock and warrants contained in our Registration Statement on Form 8-A filed with the SEC on&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1841330/000121390021047666/ea145530-8a12b_pasithea.htm">September
    13, 2021</A>, including any amendments and reports filed for the purpose of updating such description, including the description
    of our common stock included as <A HREF="http://www.sec.gov/Archives/edgar/data/1841330/000121390024027508/ea020041501ex4-7_pasithea.htm">Exhibit 4.7</A> to our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the
    SEC on&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1841330/000121390024027508/ea0200415-10k_pasithea.htm">March 29, 2024</A>.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
reports and other documents that we file with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of
the initial registration statement and prior to effectiveness of the registration statement, and after the date of this prospectus but
before the termination of the offering of the securities hereunder will also be considered to be incorporated by reference into this
prospectus from the date of the filing of these reports and documents, and will supersede the information herein; provided, however,
that all reports, exhibits and other information that we &ldquo;furnish&rdquo; to the SEC will not be considered incorporated by reference
into this prospectus. We undertake to provide without charge to each person (including any beneficial owner) who receives a copy of this
prospectus, upon written or oral request, a copy of all of the preceding documents that are incorporated by reference (other than exhibits,
unless the exhibits are specifically incorporated by reference into these documents). You may request a copy of these materials in the
manner set forth under the heading &ldquo;<I>Where You Can Find More Information</I>,&rdquo; above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will provide you without charge, upon your oral or written request, with a copy of any or all reports, proxy statements and other documents
we file with the SEC, as well as any or all of the documents incorporated by reference in this prospectus or the registration statement
(other than exhibits to such documents unless such exhibits are specifically incorporated by reference into such documents). Requests
for such copies should be directed to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pasithea
Therapeutics Corp.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Atten:
Tiago Reis Marques</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
Executive Officer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1111
Lincoln Road, Suite 500</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Miami
Beach, Florida 33139</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone:
(786) 977-3380</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3,743,905
Shares of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Issuable
Upon Exercise of Outstanding Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>,
2024</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART
II</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INFORMATION
NOT REQUIRED IN PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
14. Other Expenses of Issuance and Distribution.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table indicates the expenses to be incurred in connection with the offering described in this registration statement, other
than underwriting discounts and commissions, all of which will be paid by us. All amounts are estimated except the SEC registration fee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-style: normal">Amount</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left">SEC Registration Fee</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-style: normal; font-weight: normal">$</FONT></TD><TD STYLE="width: 9%; font-weight: bold; text-align: right"><FONT STYLE="font-style: normal; font-weight: normal">2,854.50</FONT></TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Legal Fees and Expenses</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-style: normal; font-weight: normal">50,000</FONT></TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Accounting
    Fees and Expenses</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">25,000</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Transfer Agent and Registrar fees and expenses</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-style: normal; font-weight: normal">5,000</FONT></TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Miscellaneous Expenses</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-style: normal; font-weight: normal">1,145.50</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Total
    expenses</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">$</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">84,000</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
15. Indemnification of Directors and Officers.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
102 of the DGCL permits a corporation to eliminate the personal liability of directors and officers of a corporation to the corporation
or its stockholders for monetary damages for a breach of fiduciary duty as a director or officer, except where the director breached
his duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, obtained an improper
personal benefit, in the case of a director, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware
corporate law, or in the case of an officer, a breach of fiduciary duty in any action by or in the right of the corporation. Our Certificate
of Incorporation provides that no director or officer shall be personally liable to it or its stockholders for monetary damages for any
breach of fiduciary duty as a director or officer to the fullest extent permitted by the DGCL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
145 of the DGCL provides that a corporation has the power to indemnify a director, officer, employee, or agent of the corporation, or
a person serving at the request of the corporation for another corporation, partnership, joint venture, trust or other enterprise in
related capacities against expenses (including attorneys&rsquo; fees), judgments, fines and amounts paid in settlement actually and reasonably
incurred by the person in connection with an action, suit or proceeding to which he was or is a party or is threatened to be made a party
to any threatened, ending or completed action, suit or proceeding by reason of such position, if such person acted in good faith and
in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding,
had no reasonable cause to believe his conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation,
no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable
to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the
adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity
for such expenses which the Court of Chancery or such other court shall deem proper.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Incorporation and Bylaws provide that we will indemnify each person who was or is a party to or is threatened to be made
a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative
by reason of the fact that the person is or was a director, officer, employee or agent of us, or is or was serving at the request of
us as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise (all such
persons being referred to as an &ldquo;Indemnitee&rdquo;), or by reason of any action alleged to have been taken or omitted in such capacity,
against all expenses (including attorneys&rsquo; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred
in connection with such action, suit or proceeding and any appeal therefrom, if such Indemnitee acted in good faith and in a manner he
or she reasonably believed to be in, or not opposed to, our best interests, and, with respect to any criminal action or proceeding, he
or she had no reasonable cause to believe his or her conduct was unlawful. Our Certificate of Incorporation and Bylaws provide that we
will indemnify any Indemnitee who was or is a party to an action or suit by or in the right of us to procure a judgment in our favor
by reason of the fact that the Indemnitee is or was a director or officer, or is or was serving at our request as a director, officer,
partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise,
or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys&rsquo; fees)
and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred in connection with such action, suit
or proceeding, and any appeal therefrom, if the Indemnitee acted in good faith and in a manner he or she reasonably believed to be in,
or not opposed to, our best interests, except that no indemnification shall be made with respect to any claim, issue or matter as to
which such person shall have been adjudged to be liable to us, unless a court determines that, despite such adjudication but in view
of all of the circumstances, he or she is entitled to indemnification of such expenses. Notwithstanding the foregoing, to the extent
that any Indemnitee has been successful, on the merits or otherwise, he or she will be indemnified by us against all expenses (including
attorneys&rsquo; fees) actually and reasonably incurred in connection therewith. Expenses must be advanced to an Indemnitee under certain
circumstances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into indemnification agreements with each of our directors and officers. These indemnification agreements require us, among
other things, to indemnify our directors and officers for some expenses, including attorneys&rsquo; fees, judgments, fines and settlement
amounts incurred by a director or officer in any action or proceeding arising out of his or her service as one of our directors or officers,
or any other company or enterprise to which the person provides services at our request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain a general liability insurance policy that covers certain liabilities of our directors and officers arising out of claims based
on acts or omissions in their capacities as directors or officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
any underwriting agreement we enter into in connection with the sale of our common stock, the underwriters will agree to indemnify, under
certain conditions, us, our officers and directors, and persons who control us within the meaning of the Securities Act, against certain
liabilities.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
16. Exhibits</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify; width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1841330/000121390024000296/ea190803ex3-1_pasithea.htm">Second Amended and Restated Certificate of Incorporation of Pasithea Therapeutics Corp., dated December 29, 2023. (incorporated by reference to Exhibit 3.1 of the Company&rsquo;s Form 8-K, filed with the Commission on January 2, 2024).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1841330/000121390024000296/ea190803ex3-4_pasithea.htm">Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation of Pasithea Therapeutics Corp., dated December 29, 2023 (incorporated by reference to Exhibit 3.4 of the Company&rsquo;s Form 8-K, filed with the Commission on January 2, 2024).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1841330/000121390024000296/ea190803ex3-2_pasithea.htm">Second Amended and Restated Bylaws of Pasithea Therapeutics Corp., dated December 29, 2023, (incorporated by reference to Exhibit 3.2 of the Company&rsquo;s Form 8-K, filed with the Commission on January 2, 2024).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1841330/000121390024083408/ea021586301ex4-1_pasithea.htm">Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on September 30, 2024).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1841330/000121390024083408/ea021586301ex4-2_pasithea.htm">Form of Warrant (incorporated by reference to Exhibit 4.2 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on September 30, 2024).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1841330/000121390024083408/ea021586301ex4-3_pasithea.htm">Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.3 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on September 30, 2024).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea021652901ex5-1_pasi.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Lowenstein Sandler LLP.</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1841330/000121390024083408/ea021586301ex10-1_pasithea.htm">Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on September 30, 2024).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1841330/000121390024083408/ea021586301ex10-2_pasithea.htm">Form of Registration Rights Agreement (incorporated by reference to Exhibit 10.2 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on September 30, 2024).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea021652901ex23-1_pasi.htm">Consent of Independent Registered Public Accounting Firm &ndash; Marcum LLP.</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea021652901ex5-1_pasi.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Lowenstein Sandler LLP (Included in Exhibit 5.1).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="#poa_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power of Attorney (included in the signature page)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">107*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea021652901ex-fee_pasi.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing Fee Table.</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed herewith.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
17. Undertakings</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The undersigned registrant hereby undertakes:</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1) </FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</FONT></TD></TR>
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the &ldquo;Calculation of Registration Fee&rdquo; table in the effective registration statement;</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Provided, however</I>, That: Paragraphs (1)(a), (1)(b) and (1)(c) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2) </FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4) </FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the registrant is relying on Rule 430B:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the registrant is subject to Rule 430C, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be a part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any preliminary prospectus or prospectus of the registrant relating to the offering required to be filed pursuant to Rule 424;</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The portion of any free writing prospectus relating to the offering containing material information about the registrant or its securities provided by or on behalf of the registrant; and</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any other communication that is an offer in the offering made by a registrant to the purchaser.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That, for the purposes of determining any liability under the Securities Act of 1933, each filing of the registrant&rsquo;s annual report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan&rsquo;s annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the forgoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all
of the requirements for filing on Form S-3 and has duly caused this Registration Statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in the City of Miami Beach, State of Florida, on October 7, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PASITHEA
    THERAPEUTICS CORP.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Dr. Tiago Reis Marques </I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Tiago Reis Marques</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Chief Executive Officer
    and Director </I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="poa_001"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>POWER
OF ATTORNEY AND SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
person whose signature appears below constitutes and appoints Tiago Reis Marques and Daniel Schneiderman and each of them singly, his
or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or
her name, place and stead, in any and all capacities, to sign any and all amendments (including, without limitation, post-effective amendments)
to this registration statement and any and all additional registration statements pursuant to Rule 462(b) of the Securities Act and to
file the same, with all exhibits thereto and all other documents in connection therewith, with the SEC, granting unto each said attorney-in-fact
and agent full power and authority to do and perform each and every act in person, hereby ratifying and confirming all that said attorneys-in-fact
and agents or either of them or their, his or her substitute or substitutes may lawfully do or cause to be done by virtue hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons on behalf of
the registrant in the capacities and on the dates indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; width: 32%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature</B></FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; width: 1%; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; width: 40%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; width: 1%; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; width: 26%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Dr. Tiago Reis Marques</I></FONT></TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Executive Officer and Director</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Principal Executive Officer)</P></TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 7, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Tiago Reis Marques</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Daniel Schneiderman</I></FONT></TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Financial Officer</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Principal Financial and Accounting Officer)</P></TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 7, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daniel Schneiderman</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Prof. Lawrence Steinman</I></FONT></TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 7, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prof. Lawrence Steinman</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Simon Dumesnil</I></FONT></TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 7, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Simon Dumesnil</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Dr. Emer Leahy</I></FONT></TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 7, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Emer Leahy</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Alfred Novak</I></FONT></TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 7, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alfred Novak</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">II-6</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>ea021652901ex5-1_pasi.htm
<DESCRIPTION>OPINION OF LOWENSTEIN SANDLER LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
5.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="ex5-1_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
7, 2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pasithea
Therapeutics Corp.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1111
Lincoln Road, Suite 500</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Miami
Beach, Florida 33139</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have acted as counsel to Pasithea Therapeutics Corp., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), in connection with the
Company&rsquo;s Registration Statement on Form S-3 (the &ldquo;<B>Registration Statement</B>&rdquo;) under the Securities Act of 1933,
as amended (the &ldquo;<B>Securities Act</B>&rdquo;). The Registration Statement relates to the offer and sale by the selling stockholders
identified therein of up to 3,743,905 shares of the Company&rsquo;s common stock, par value $0.0001 per share (the &ldquo;<B>Common Stock</B>&rdquo;).
Such shares of Common Stock consist of: (i) 1,219,513 shares of Common Stock (the &ldquo;<B>Pre-Funded Warrant Shares</B>&rdquo;) issuable
upon the exercise of pre-funded warrants (the &ldquo;<B>Pre-Funded Warrants</B>&rdquo;); (ii) 1,219,513 shares of Common Stock (the &ldquo;<B>Series
A Warrant Shares</B>&rdquo;) issuable upon the exercise of series A warrants (the &ldquo;<B>Series A Warrants</B>&rdquo;); (iii) 1,219,513
shares of Common Stock (the &ldquo;<B>Series B Warrant Shares</B>&rdquo;) issuable upon the exercise of series B warrants (the &ldquo;<B>Series
B Warrants</B>&rdquo;); and (iv) 85,366 shares of Common Stock (the &ldquo;<B>PA Warrant Shares</B>&rdquo; and together with the Pre-Funded
Warrant Shares, the Series A Warrant Shares and the Series B Warrant Shares, the &ldquo;<B>Warrant Shares</B>&rdquo;) issuable upon the
exercise of placement agent warrants (the &ldquo;<B>PA Warrants</B>&rdquo; and together with the Pre-Funded Warrants, the Series A Warrants
and the Series B Warrants, the &ldquo;<B>Warrants</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with rendering this opinion, we have examined the Second Amended and Restated Certificate of Incorporation, as amended, the
Second Amended and Restated Bylaws of the Company, the forms of the Warrants, such other corporate records, agreements, documents and
instruments, and such certificates or comparable documents of public officials and of officers and representatives of the Company, and
we have made such inquiries of such officers and representatives, as we have deemed necessary or appropriate for the purposes of this
opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
such examination, we have assumed the genuineness of all signatures, the legal capacity of all natural persons, the authenticity of all
documents submitted to us as originals, the conformity of original documents of all documents submitted to us as certified, conformed
or photostatic copies and the authenticity of the originals of such latter documents. As to all questions of fact material to these opinions
that have not been independently established, we have relied upon certificates or comparable documents of officers and representatives
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the foregoing, and subject to the qualifications stated herein, we are of the opinion that when issued in accordance with the terms
of the Warrants, the Warrant Shares will be duly authorized, validly issued, fully paid and non-assessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
opinions expressed herein are limited to the corporate laws of the State of Delaware, and we express no opinion as to the effect on the
matters covered by this letter of the laws of any other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the filing of a copy of this opinion letter as an exhibit to the Registration Statement. In giving such consent, we
do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act of 1933,
as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"></TD>
    <TD STYLE="width: 40%">Very truly yours,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Lowenstein Sandler LLP</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lowenstein Sandler LLP</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex5-1_002.jpg" ALT=""></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>ea021652901ex23-1_pasi.htm
<DESCRIPTION>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - MARCUM LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><U>INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM&rsquo;S
CONSENT</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">We consent to the incorporation by
reference in this Registration Statement of Pasithea Therapeutics Corp. on Form S-3 of our report dated March 28, 2024, which includes
an explanatory paragraph as to the Company&rsquo;s ability to continue as a going concern, with respect to our audits of the consolidated
financial statements of Pasithea Therapeutics Corp. as of December 31, 2023 and 2022 and for the years ended appearing in the Annual Report
on Form 10-K of Pasithea Therapeutics Corp. for the year ended December 31, 2023. We also consent to the reference to our firm under the
heading &ldquo;Experts&rdquo; in the Prospectus, which is part of this Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-decoration: none"><I>/s/
  Marcum <FONT STYLE="font-size: 10pt">LLP</FONT></I></FONT></TD>
  <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Marcum <FONT STYLE="font-size: 10pt">LLP</FONT></FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT>New
Haven, CT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">October 7, 2024</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>4
<FILENAME>ea021652901ex-fee_pasi.htm
<DESCRIPTION>FILING FEE TABLE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 107</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Calculation of Filing Fee Tables</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Form S-3</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Form Type)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Pasithea Therapeutics Corp.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Security</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Type</B></P></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Security <BR>
Class Title</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Fee</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Calculation</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>or Carry</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Forward</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Rule</B></P></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Amount</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Registered <BR>
(1)</B></P></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Proposed</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Maximum</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Offering</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Price Per</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Unit (2)</B></P></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Maximum <BR>
Aggregate <BR>
Offering</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Price (1)</B></P></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fee Rate</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Amount of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Registration</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Fee</B></P></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 7%; font-weight: bold; text-align: left">Fees to Be Paid</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 6%; text-align: left">Equity</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 17%; text-align: left">Common Stock, par value $0.0001 per share</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 7%; text-align: left">Other</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">3,743,905</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">4.98</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">18,644,646.90</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">0.0001531</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,854.50</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Total Offering Amounts</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,854.50</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Total Fees Previously Paid</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Total Fee Offsets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="padding-bottom: 4pt; font-weight: bold; text-align: center">Net Fee Due</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,854.50</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 0.25in">(1)</TD>
    <TD STYLE="text-align: justify">Pursuant to Rule 416 under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), there is also being registered hereby such indeterminate number of additional common shares as may be issued or issuable because of stock splits, stock dividends stock distributions, and similar transactions.</TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">(2)</TD>
    <TD STYLE="text-align: justify">Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) under the Securities Act based on a per share price of $4.98, the average of the high $5.36 and low $4.60 reported sales prices of the registrant&rsquo;s common stock on the Nasdaq Capital Market on October 1, 2024.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  ] 24# 2(  A$! Q$!_\0
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MIQJ0E&2Y54IJ"34GJ[-/KUZ>A_1'_P &NOP^T_X>_L>_M._'C5HH=.T_QO\
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M\>:W87$0GMKE_">K>;>Z=+?0%)K2W\4W&B7DJRQ&XAM@^X>+_LL_M>?M>?\
M!*?]HG4(- 7QAX-U#P-XJ_L/XV_LT>,;F]L_"?BVVL98?[8\/ZWX:>6XTS2O
M$,VG.)_"WCG0XOMEJ\]AJ%G?:GH5U-:WOW9_Q$?_ /!4G_G\^#'_ (8G4_\
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MOCGP9)J#,FG1R>$OA%X?UWQLVGM.1$++^V+"'[682+<ZI_:._P#THW1KY"^
M7_!K-\=]9\1Z9=_M._M#_#CP5X(BNXY=7T+X*VNO^+_'&J62#?+8V?B#Q=HG
MASPYX<GN6'D#4?[)\4&WC9IX[(RJB'^FKXP?L+:%%_P3M^(G[!?[*3>&?@QH
MNO\ PBU7X3>#=1URWU75]*TBS\22+!XIUGQ&UA,FM:]K'B"RO-=N]7U*2X-Y
MJFM:I+>7DC++**]WB'/,EJY9@,APV85,QC];P"Q68UW.K[+#4,0I5*M6NZ5-
MUJTH3G&U*G+DI0]Z<Y.*E$(34G-KET=HK2[:V2OHC_,O^%OA?6/C=\8?AKX-
MDBN=1U[XR_%OP5X?NXU)>ZNK_P"(_CG3+35').7:0?VS=SRL<N%1W.2#7^G=
M_P %$=/U30?^"<_[8.C^!+*Y%WI7[*?Q=T?1[+34;[3#I=M\.=8T^XBLXX )
M/,MM%6Y,20*)/W8$(#[!7\_W[&'_  ;=_&?]G#]J_P#9^^/GC[]HOX0^-?"/
MP;^(FF^/]3\*^'_!?C&PUG6KC0;'4)=#@L;S5-0FT^W>W\0MI-],]S$ZFUM9
MTC43/$R_UP7EG::C:76GZA:V]]87UM/9WME=PQW%K>6EU$T%S:W-O,KQ3V]Q
M"[Q30RHT<L;LCJRL0?/XRS_ X[,,FJ9?6IXS#Y>WB)J"J0A[58O#35%JI2IV
M_<X2*NH224UO9Q*I0:4^96<M/E9Z_>S_ ":_V1/B+X%^#_[4'[-'Q:^)-E?Z
MG\./AG\:/AEX[\9VFD6JW^I2^&?#/B/3M5OYM.L"\8O[FUAMQ>Q62R(]Y]G^
MSPL)9(Z_TA/@G_P5G_X)]?M&_%?P+\$?@G^T7X>\?_$WXBV>N7GAOPUIGA_Q
MG8R,OAW0KCQ'J=MJ%_K?AS2],T[4$TJTO)H--N;Q;ZZDM+F&"!Y(F%?@9^V=
M_P &P.JZ[X]\0^.?V'_BUX+\*>$O$.I7NL+\%?B_%KUKIW@Z:]F-S-I'@7QU
MX;TW7;J7PY%-+,NCZ)XCT!KC1[-8+ >(KR"&/9D_L(?\&Y_[7GP*_:5^"?[0
MGQ,_:)^#G@6+X/\ C_P_X^@TGX9V7BWQYXFUP:/.YU+PM<W'B'2/!F@:9IWB
M32Y;S0=3OTDUQX]/U*ZDAL6G2+/K9_BN$^(L+#'U,XGA\5AL%B(8?#/GC-UI
MIUJ=.OAWAJLI-8B,82G1K*,X2;4^5)J8*I!\O+=-J[\MM'==.YP__!U=\3FU
M#XQ?LB?!B&\9H?"WP\^)'Q1U&P5@8UO/&/B#1?".C74H!^6>.T\(:[%"& /D
MW4Q VR U]!_\&IWPO:R^&?[7GQINK)0WB?XA_#_X9Z-J#)B1[/P1X9O_ !'K
M-O'(5RT'V_QQ8EE5BHGA<,H=37MW_!4W_@AO^T'_ ,%"/VM=5_:"\-?M"_"C
MP)X0C^'W@CP%X7\)^)_"7C'5]:TVU\-Q:G>ZK<7=[I5_;V#C4M>UO4KJ"."(
M>7:^0)29C(:_47_@E/\ L)ZU_P $[_V3;#]G_P 4>,]!^('BR?XA>._B!XD\
M5>&M,U#2-&OKWQ9J%N+&WLK+5)9[^---T+3=)T]VGE;?-;RO'B-E%>3C,XRR
MGP1A,HPN+IU<=-87ZS0A&JI0YL37Q>(YI2I0IOEDJ,)6J3N]%S)75*,O:N35
MEK9Z=DE^I^DE?Y0W[>GQ6E^,?[9'[7?Q;24W<7BOX\?%>^TC8_G!]&T7Q'J/
MA[PW! V3OC.C:)IT=NH9@%945F !/^JYXHM=:OO#7B*Q\-WMMIOB*\T+5[70
M=1O5F>SL-:N-/N(=+O;M+?\ ?M;6M\\$\ZP?OFBC<1?.5K^++P[_ ,&L'[1=
MOXD\/:IXG_:L^!^JZ9;^*M#UGQ/:VW@'QZ+K5=,AU^TU/Q#:VS7&JF(76I62
MWT%L]QF%;B>-Y]T8<'+@7,LJRJKF6)S'%T\-.I2P]&A&<:LI5(*I5KUN7V=*
MHE[T*4-7&[DMTFT5HRERJ*;W;V]._J?L=^T9^P]KGQ%_X(/:%^RSX T6YN_'
M_@C]ESX/^+?"7A\1.;_5O'_PXTKPU\1+_0T@C423ZMXBU&PUG2K6+ >;5M2@
MW99FS_$Q_P $[OVOY?V&_P!K3X9_M$7/A9_&7A;1/[9\*?$?P8\,"ZEJW@/Q
M7;KIOB6+3(=0\J"'Q1H,T%IK>CVU]);0S:KHZZ5?2VT-W/+%_J?000VL$-M;
MQI#;V\4<$$,8"I%#$@CBC11PJ(BJJ@<  "OYS/\ @H?_ ,&[?P0_:L\;>)?C
M9^SQXW3]G#XO^+=0O-<\9:'-H1\0_!_QSX@OG\Z]UZZ\/65SIVK>#/$&J7!D
MN=8U3PU=SZ9J5U+)?W?AJ;4YKF^N*X9XEP-*GFF69VI+!9K7Q&(=9*<XTZF+
MYUB*=7V=ZL85%*$X5H1DZ56FG*+BU*)4IMN,H;Q25O3:W^78^IM#_P""W'_!
M(G6O!UOXQE_:-\!:$9=/6]G\)^(/A]XOL/'-C,8V=M+N?#$?A"YO)-21U,)C
ML6O+5I"#%=R1,)3Q'[$W_!:;]CK]N/\ :F\6?LU> O &J^"@/#BZU\'?&7Q!
MTK0]%;XRWFCBZG\:Z/I?AA89;_PUJ.CZ:+76M"L-8NWU3Q%HMMK]\]AI,ND&
MSN/YY(_^#8'_ (*#-K?]FR?$K]EJ+21/L/B/_A,?B-);FW\P*9TTH?#5=2,G
ME?O!;N(P7'E&=0?-K]M/^"=__!O#\$OV2O'GA+XZ_';XAW_[0/QJ\#ZO8^)/
M MGIFGW7@GX6^ ?$NFS&?3_$&G:-'J%YX@\5:_ITH233]1\1:K#I5JYDDC\-
M+<&.X1X_+^!\'@\7.AF^+QV*JTIK!0HU'6=&KI*FY1AA\-3E&Z4*DL355J<I
MN--U5$%*JVKQ25];Z777J_P7X'FO_!S]^SEK7C?]DWX,?'CPEH_VFQ_9P^)&
MJ6_C.WTZU(&C^ /BIIMEHESK\D<"B&#3M)\6Z+X3@OY758[:WU>6Z=ECAE-?
MSP?\$;/^"F&F?\$W?CWXOU7XAZ%KGB3X%_&?0=%\.?$NW\,0)?>)O"^I^&+V
M^N_"GCG1=)EGMH]<72TUC7-,UK18YH[^\TW5%N=.:>]TV&QO/]'7QCX/\+?$
M'PIXC\"^.- TKQ5X.\7Z)J7ASQ1X:URSAU#1]=T+6+26QU/2M2LIU>&YL[VT
MGE@GB=2&1S@AL$?Q_P#[67_!KAXAF\5ZMXE_8H^-WA;3O!VI74MY:?";XZ#7
MTN/"L<KLYTKPW\1_#FG:]=ZQI5ON\O3;;Q1X>74[:W5(;SQ)J#QB:3;AG/LH
MJ9-7X=SZ?L</.57V->7M%3E3K5(UG"56G"I*A6HXB/M:-24)0:E9M2BXS52$
ME)3AJ^J_#YIK<_4+XM_\'&O_  32\ >"Y=?\">/O&OQN\5SV$D^D^ ? _P /
M/%VD:E+J!M_-M['7M<\;:1X<\/\ AR%IBL%U=W%[=R6Y$K065Z\8A?\ A;_;
M'_:B\7_MC_M(_%K]IWQ[I.F^'M=^).K6E\GAK2+B>\TSPSX>\/:+8>'O#7AZ
MVOKI(9]0;3=#TJT2]U&6&V_M#47O+R.UM(9H[:'^@?X$?\&M'[1.N^(K&X_:
M2_:#^%WP_P#!45TCZEIOPAM?$'COQQJ-I&VZ6ULM0\4:+X6\,Z#)= >5'J,M
MOXD-L&,QTJ5D6-^I^(G_  :M?%W6O&_C27X>_M+_  F\*?##4_$NL#P9X?UK
MPOX]U_Q5H7@:XO9(M(L-7UXWUO;ZOXEMM&,9O]22UM[*YU8RS0VT%H8X4]O)
ML3P/D&(K/"9FZM>I24:F+KNM6BJ3J)^PI2I82G34FTIS4*;<E"/-56E,F2JS
M2O&R[*R^;N_Z['](7_!)/X62?!O_ ()M?L<>"+FT6ROS\%/#7C#580@CD_M7
MXD&Y^(FHR3KM4_:9+OQ3*TY<>9YA8/\ ,#17WCX.\-6/@OPCX6\':6,:9X3\
M.:'X:TX8"XL="TRUTNT&T<+BWM8Q@<#I17Y+C*[Q6+Q6*EOB<3B*[_[C5ZM5
M;]E.*^1T)6279)?<B?Q._B"/PUXA?PE%I\_BI-#U9_#,&KO)'I4WB!;"X.C1
M:F\)69-/DU(6R7KQ,)%MC*4(8 U^7?[(&N_\%5;N_P#C(/VK_#WPXT[3[?X=
M:E<?"JX<^"K6 _%%))AI=E,? VIWD\O@QHP7U2ZU=4O(XX[5K2ZDDDN@/U@K
MSKXN?#/0OC-\,?'7PI\3WFMZ?X>^('AK5/"VKWWAO4I-'UVUL=5MVMYI],U*
M-)#;74:MN1GBF@D :&X@FMY)8G]7*LUH8/#8O+L1EV4XBCF5? JKF>,R^>.S
M'*Z-#$49UJF6N&+PUN>E&I[:B]<3'FI*K3]JI4\ZE-RE&:G43@I6A&:C";::
M2G[LMG:SZ;V=M?YMM8^&W_!<+7/C'X9^/M]X5T]OB;X/\+:SX+\/7^DZG\$%
M\+VWAGQ!=PWVM:7%H)UE]-U.RU2]M;*Z%]?B>_86.FR1W436ZY^ROVT/#O\
MP5C^(_PN^&?P[^'_ (;\#W>D^/O@3#H'[25GX0OO!-IJ#_$/5A<V?C#1;/4O
M%FI0M8>';W1IK>V@G\+R2J]Q-K,0OEMA8.^K_P %"_ 'CS]EG]ACX/\ @?\
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COK;?6X4445@,**** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ex5-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !" -@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#YW'_!43_@
MHD,?\9A_&KIT_MVPXZ#&?[+/YXY]LTO_  ]%_P""B7_1X7QI_P#!]8?_ "HK
MX+. .%R?=2._T_\ U]*G%I?'IIFH$<8(TZ]YR,YYM^GH0!^-?RLLTS1[9EF;
M_P"ZEF&^_P#T'=M?RN?]E;\%?!96OX0>$T;WMS>&WA_':U_BX1A>UUM>VETC
M[M_X>B_\%$O^CPOC3_X/K#_Y44?\/1?^"B7_ $>%\:?_  ?6'_RHKX-9'C<Q
MSP20.-I*30R0R!6.%8I*B-AL$KD#< Q7(5C33M SM'7G*D #GG.#TQZ$8SDC
MJ'_:F:;?VGF7_ARS#],;]ZW75+2Y_P 05\%[7_XA!X3M;W7AKP"U:U[IKA!I
MJW5-_?H?>G_#T7_@HE_T>%\:?_!]8?\ RHH_X>B_\%$O^CPOC3_X/K#_ .5%
M?#NBZ)KGB6_72O#6@ZQXCU1R@73- TJ_UK4"S_<4VFFVUS,&D/$>4 <XP22!
M7;>(?@U\8O"-F=1\5_"#XH>&M-"[SJ.O_#[Q;I-B$()5S<WNCPPA !N+LZIC
MD9Z&UF&<2C*<<?FTH1OS3CCLSE"-E=MSCBI0276\TX_:43AQ'A3X!X3$T<%B
M_#/P4PF-Q%OJ^"Q?!'A?A,;B+NR]A@L7D.%QE>[T7L<)6NW9-]/JS_AZ+_P4
M2_Z/"^-/_@^L/_E17N'[+W_!2+]O7Q?^TQ^SYX4\4?M8_&'6_#7B;XU_#30=
M?T:]URQDLM5T?5?%NE6FI:;=H-,1GM;VTEEMIT4J3#,X5E;##\F8WCD7<FUE
M/1DPZGUP5!'!R#[@CJ"!]'_L>8_X:X_9>Q_T<%\)/_4ST;V&/I6N#S3,Y8O"
M)YEF+3Q6%3B\QQ\HRB\3ADXR3QLDXM-IIIIIM-6<D_%XZ\&/!W#\#\;UZ/A'
MX6T,1A^"^,J]"M2\-^!*5>A7H<)<55J%>C5I\(PJ4JU&M1I5J-6G.%2E5I4J
ML)0G3IRA_IS445\$_MH_\%,OV-?^"?=[X T_]JSXJ2?#B[^)UOKMUX+BC\)^
M*_$W]JP>&WT^/6'9O#6D:HMF+5]4LE'VQH/-,W[K?M;']0'_ !^;[*_H?>U%
M>3_ SXV_#G]H_P"$7P[^.WPAUQO$_P ,/BIX8T_QAX(\0/87^E/JV@:HADL;
MYM.U2WM-0L_.56_<7=M#.F/GC45ZQ0 4444 %%%% !1110 4444 %%'TK\U-
M"_X*Z?L%^)/VNYOV%=(^,LMU^TY;^/\ Q'\,9OA__P (5XSBC3QIX4TS4]8U
MS2O^$AET1/#[+9Z=H^H3B\&I&TG\@I!*\CJA!I-[*_H?I712 Y'/7O\ Y.#^
M8%!. 2.3Z=,^W?\ E0(6BOS#U_\ X+$_\$^O"_[7T/[".M_'%;/]J"X^(_AO
MX30_#K_A#O&,I;QYXML-*U/0-&_MV+17T+%]9ZUITHO#J LX3.8YIHY(Y$7]
M.QG'/6@!:*** /\ *2M]QN[+(4@W]CD8)S_ID'&#P1Z@]J_U(?!W@GP8WA'P
ML[>$/"Y=_#FAL[?\(_I(+,=+M22<6@'4G@<#L*_RWK;'VNQ^8G_3[#C.?^7R
M#M7^J1X,_P"1/\)_]BUH7_IKM:_'_"Z,93SKFC&7NX#>*>\L5?=/LON79'^Y
MG[8G$8C#X+Z/SP^(Q&'<\7XEJ;P^(KT'-1PW!O*INA7H.:C=\O-S6N[6N[_P
MP?\ !P#IVG:5_P %#=0M=+L++3;4?!3X6N+?3[2WLX-[S>*=\GDVT<<9D8 !
MG*EB JDD* /F?_@E_P#L,3_M[_M)VWP[UJ^U+1?A5X(T;_A.?BQK6DND.J'P
M[#>PV&G^&=&NI4DCMM:\4ZE.M@EYY<KZ;IT6IZC%!-+:(*^I?^#@_P#Y2)ZF
M>P^"'PL)[\>;XI[=SG&/>OJ7_@VD^(_A'0?C)^TM\,=4N[6V\8>/O _@3Q+X
M4BG>**XU:P\!:IXG@\2V-AYA62YN;>/Q5INI26L&YS:6MU=%/*MG=/!^I83'
M^(.)PF,:^K5<\Q2G3;Y8U?94X588>]XV5:<(TVHV;CS16LTU_2,>/N,_#?\
M9C<-\=<"3Q*XOR;P!X2GEV8TJ4L9BLH699C'*,QXBA&K#%<]?(LMS7&9K2K5
MX5J>'KT\/CJRG3P+1_2_H'@;]DS]@7X-:MJ^B>'OAQ^S_P#"7P-I$<WB+Q(F
MG0Z>PM1+#;QW.N:V(;GQ#XFU?4;QX(8OM=QJ>K:IJ$L,%NEQ<211MX[\"?\
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M3I=6,UT%1A9SYHW;4G%;W>^R>N_4^^OAQ_P6!_X*6_\ !/W]O+Q#_P $Z_\
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M (2T^W\3:?X8T(Z+H=M=ZIJ136-5U_3=*N0EG\G?\'9=O<R_$/\ 8 ,%K=W
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M?]K'X'?\%>/$O[.OCOXF_L$?MLV/P,^._C#PA>_:!-I5AIWAWPYX>^('P/\
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M2TDB+-*LR,]M<VDL<]K>VLDMI=6\UO++$_\ H_?&W]@']CG]HWQS+\2?C=\
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M:9FZ->KPS6HPS*G4X=PV Q>+EAJ/$&#K1X=AED/KU;*_;T:>7TC]A_C/\(/
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M]CJ?]MBQB>Y@TV2UMKB6'^+_ /;+\2?'#XC?\' .BZ1;^"O /Q0\?^#OBY\
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M4]3L@VH6=U"MO_1W2!0.@_R*!*4E:SVNUY7W^\_C[^(G_!I?X;^+/AWP9/\
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; %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ex5-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  F I4# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^Z[XH?&'X
M:_!?1K#Q#\4/%EAX0T74]4CT6PO]0AOYXKG5);6ZO8[-%T^TO)5D:ULKJ8,\
M:Q[86!<,5!\/_P"&\OV1?^BW^&?_   \2?\ RDKZZHH ^1?^&\OV1?\ HM_A
MG_P \2?_ "DH_P"&\OV1?^BW^&?_   \2?\ RDKZZHH ^1?^&\OV1?\ HM_A
MG_P \2?_ "DH_P"&\OV1?^BW^&?_   \2?\ RDKZZHH ^1?^&\OV1?\ HM_A
MG_P \2?_ "DH_P"&\OV1?^BW^&?_   \2?\ RDKZZHH ^1?^&\OV1?\ HM_A
MG_P \2?_ "DH_P"&\OV1?^BW^&?_   \2?\ RDKZZHH ^1?^&\OV1?\ HM_A
MG_P \2?_ "DH_P"&\OV1?^BW^&?_   \2?\ RDKZZHH ^1?^&\OV1?\ HM_A
MG_P \2?_ "DH_P"&\OV1?^BW^&?_   \2?\ RDKZZHH ^1?^&\OV1?\ HM_A
MG_P \2?_ "DH_P"&\OV1?^BW^&?_   \2?\ RDKZZHH ^1?^&\OV1?\ HM_A
MG_P \2?_ "DH_P"&\OV1?^BW^&?_   \2?\ RDKZZHH ^1?^&\OV1?\ HM_A
MG_P \2?_ "DH_P"&\OV1?^BW^&?_   \2?\ RDKZZHH ^1?^&\OV1?\ HM_A
MG_P \2?_ "DH_P"&\OV1?^BW^&?_   \2?\ RDKZZHH ^1?^&\OV1?\ HM_A
MG_P \2?_ "DH_P"&\OV1?^BW^&?_   \2?\ RDKZZHH ^1?^&\OV1?\ HM_A
MG_P \2?_ "DH_P"&\OV1?^BW^&?_   \2?\ RDKZZHH ^1?^&\OV1?\ HM_A
MG_P \2?_ "DH_P"&\OV1?^BW^&?_   \2?\ RDKZZHH ^1?^&\OV1?\ HM_A
MG_P \2?_ "DH_P"&\OV1?^BW^&?_   \2?\ RDKZZHH ^1?^&\OV1?\ HM_A
MG_P \2?_ "DH_P"&\OV1?^BW^&?_   \2?\ RDKZZHH ^1?^&\OV1?\ HM_A
MG_P \2?_ "DH_P"&\OV1?^BW^&?_   \2?\ RDKZZHH ^1?^&\OV1?\ HM_A
MG_P \2?_ "DH_P"&\OV1?^BW^&?_   \2?\ RDKZZHH ^1?^&\OV1?\ HM_A
MG_P \2?_ "DH_P"&\OV1?^BW^&?_   \2?\ RDKZZHH ^1?^&\OV1?\ HM_A
MG_P \2?_ "DH_P"&\OV1?^BW^&?_   \2?\ RDKZZHH ^1?^&\OV1?\ HM_A
MG_P \2?_ "DH_P"&\OV1?^BW^&?_   \2?\ RDKZZHH ^1?^&\OV1?\ HM_A
MG_P \2?_ "DH_P"&\OV1?^BW^&?_   \2?\ RDKZZHH ^1?^&\OV1?\ HM_A
MG_P \2?_ "DH_P"&\OV1?^BW^&?_   \2?\ RDKZZHH ^1?^&\OV1?\ HM_A
MG_P \2?_ "DH_P"&\OV1?^BW^&?_   \2?\ RDKZZHH ^1?^&\OV1?\ HM_A
MG_P \2?_ "DH_P"&\OV1?^BW^&?_   \2?\ RDKZZHH ^1?^&\OV1?\ HM_A
MG_P \2?_ "DH_P"&\OV1?^BW^&?_   \2?\ RDKZZHH ^1?^&\OV1?\ HM_A
MG_P \2?_ "DH_P"&\OV1?^BW^&?_   \2?\ RDKZZHH ^1?^&\OV1?\ HM_A
MG_P \2?_ "DH_P"&\OV1?^BW^&?_   \2?\ RDKZZHH ^1?^&\OV1?\ HM_A
MG_P \2?_ "DH_P"&\OV1?^BW^&?_   \2?\ RDKZZHH ^1?^&\OV1?\ HM_A
MG_P \2?_ "DH_P"&\OV1?^BW^&?_   \2?\ RDKZZHH ^1?^&\OV1?\ HM_A
MG_P \2?_ "DH_P"&\OV1?^BW^&?_   \2?\ RDKZZHH ^1?^&\OV1?\ HM_A
MG_P \2?_ "DH_P"&\OV1?^BW^&?_   \2?\ RDKZZHH ^1?^&\OV1?\ HM_A
MG_P \2?_ "DH_P"&\OV1?^BW^&?_   \2?\ RDKZZHH ^1?^&\OV1?\ HM_A
MG_P \2?_ "DH_P"&\OV1?^BW^&?_   \2?\ RDKZZHH ^1?^&\OV1?\ HM_A
MG_P \2?_ "DH_P"&\OV1?^BW^&?_   \2?\ RDKZZHH ^1?^&\OV1?\ HM_A
MG_P \2?_ "DH_P"&\OV1?^BW^&?_   \2?\ RDKZZHH ^1?^&\OV1?\ HM_A
MG_P \2?_ "DH_P"&\OV1?^BW^&?_   \2?\ RDKZZHH ^1?^&\OV1?\ HM_A
MG_P \2?_ "DH_P"&\OV1?^BW^&?_   \2?\ RDKZZHH ^1?^&\OV1?\ HM_A
MG_P \2?_ "DH_P"&\OV1?^BW^&?_   \2?\ RDKZZHH ^1?^&\OV1?\ HM_A
MG_P \2?_ "DH_P"&\OV1?^BW^&?_   \2?\ RDKZZHH ^1?^&\OV1?\ HM_A
MG_P \2?_ "DK5T+]MC]EGQ+K>D>'-"^,?AW4=;U[4K/2-(T^&R\0+-?:EJ$Z
M6UG:1-+H\<2R3SND:M+)'&"P+NHR:^I:* "BBB@#\Z/^"J/[0?Q__9C_ &0-
M=^*?[+VE^&=?^.*?%;X >"_!'AGQA:&[T'Q9<?$/XU^!O!6I>$KEA-"VGW7B
MG2-;OM TO659FT74]0M-3\N5;5HV_._]H?\ X*I_$M/AS^U+\6/@YX\\+?#S
MX9>$/V:_^"=OQ=\ >)_%G@BR\0ZK\+;[]I3]ICQE\)?CK<^.=-N[M(M3U;P#
MH7AZZTB[\,ZA#%_PC?BSP]JL=S'<.)+=?UX_;*_9WUO]IWX3>'?AUH'B?3O"
M-]H?QS_9Y^+CZMJ=C=:A;RV/P5^-/@GXIZCH\4%G-!-'?:Y9>%)])L+LN8;.
M[NX;F:.6*)XV_,[XJ?\ !(#QK>>*_P#@HMXJ^"GQ@\)^'[3]LW6?V3_B#\-?
M!'Q \/Z_J_A3X/\ Q(^ _P <+OXZ?$J&[_L34[/4+[P'\7/&MQ>^)WT;1IM/
MN]#\2^)_%=W;R"WOHHXP#>L_VYM>^&=C^S-\5[+]K[PE^UW^S3\1?B9^TOX%
M^*OQ2L/ACX2\$KHFI_#S]FGQG\9/ GAW29?",5E:PWEIKOPI\1:7>/-;37.M
M7'BRRL_W2Z="3!_P3W_;H_:E_:7\5_LB_#[XO0^#O#GQ!;X ?M5_$?\ ;$\.
M:+X=$45CXV\ _&OX??"_X.Z!H%Q)=--X;2[T7Q3J'BFZC\N5M<M[=_\ 4):G
M?ZO^T]^Q%^T_^W7^RE+\$/VFOB%\ O!WQ$TO]H'X0_$[PKXL^ /AKXE6/ABW
M\"^"O%.C2^/?#FJV'CGQ)JVMR>(?&_P\O_B/X'2]LKZ'2K>#Q-937-I-'!>1
MS^Z? ']B*+X)?ML_MH?M9KXIL]3TO]J#2?@AI?A'P-;:;+:-\-E^'?AK4M.\
M?YNVFDMKR/Q_XCETGQ$$LX+5;22P>.X69VB= #Y%\0_MH_M/Z/\ M8:E^P$N
MJ>$O^%^>(?VL/"GCWP+XP;P:%TR#_@F;=^%9/BAXY^(,^D/<M87GBSPAK'A;
MQ5^RV?$,TJ0R_$#Q!X.\3/I[R7:6%QS_ ,$_VU?VK]8TC]B']J_X@^,O &L?
M +]O3]H*Z^"VG_L\:5\.DTCQ!\$?#OCW3?BAJ7P-\4Z/\5D\07.I^-O$MLGP
MWTR+XKVOB+1K?1=0;Q?J#^$+'05\.VPU;]([_P#9NO[S]N;P_P#M<'6M#.DZ
M+^REXM_9SD\,2:3(WB&>^\2_%KP?\2$UR+6R_D1Z-;VOAF?3I]+:,RRW=U'<
MJX1'5OB[X/\ _!.#XP^!-;_9Q^$WC#XU^ ?$_P"QK^QE\7=4^-G[/7@_2_A_
MKNF?'77/$*6?Q#L/AOX2^+GCJ[\6WOA&[\+_  >M_B3J8TK4?"/A;2=9\=2:
M'X;E\21Z?]FU*/50#\Z/@[_P5&_:JU7X8>&/'-O^TC\%?V@_&'Q,_9"_;T^,
MOCOX6>%_A]X.L]>_8_\ &_[-7A?7-?\ A9XA\4OX)\27UW_PA7B?7;.P\!ZM
MX=^*=CINKZSKM]8W.@ZL%M]9TZ']/?\ @FE^V+\3OV_+?Q!^T3H7BKP7>?LF
MZ'X0\(_"3P)+H6D6SZ_\8OC[X>TS3K_]H'XN27YO'N?"/PZ\.^++J7X9?#KP
M>UH+SQ"='\1^.;V=-&O_  DL_P Z^#?^".&O_#'X2^#_  E\-/B%\,/"?CS7
M/V._VJ_V/?VE_$NG> +C3]*^-OASXX)XC\1_"SQK>0:=+!J$OB[X.?$+5C?0
M:GK<E_?:IX9\3>.=&2]MGU.WD7[2_9:_8A\0?LG?&.7Q1\-_&7A>P^#GQ#^
M'PI\(?&SX1V/A^YTS3[O]HGX,>&/#OP^\._'7X<K:3+I?AU/&WPVTN/PE\2M
M!FL4?67\'?#[6XKHZC9ZN;P _1BBBB@ K@/BOXBU/PA\+?B5XMT3R1K/A?P!
MXQ\1:0;B$W%O_:>B>'=1U.P\^W#*9X?M5K%YL(9?-3<FX;LUW]<7\2/"UQXX
M^'?CWP5:7D6GW7C#P7XI\+6U_/')+#8W'B#0[[28;R:*)DEDBMI+M9I(XV61
MT0JC*Q! !_.U^SS_ ,%3/BCX7\-_!7XB?$?]J#X0?MB>%_B+_P $_/BI^UO\
M=_"OPW\(^ _#?BO]EKQQ\,/ /P[\9Z5H&K7OPS\2:Y:KX?\ B3XB\:ZE\*=$
M\+>.]-M/&LOC+2M/?2=0O9!KFD6OT'\.?VZOVL4_9)_9NU'XRP>"_#G[6^E?
M\%!_@A^Q;^UQI&F>&2OA:*X\7_$O2[?Q"_@_2[F]W:9'XE^%GBSP;KV@:RL]
MREM+JC7-LMQ&%!]FUC_@ESX:U+]@KX'?L-V)^&?A;0;&#]EOPO\ M6^)/ _@
MMO U[\>OAU\"[GPMJOCS0+74_"$FA^)-+UKXF7_A2WL5\2WNKR:OI&F:OK-R
MMZVIS+,_C7CS_@D9XM\"ZE\2)_V.?B%X,\#^&O$OQ\_8U_:J\*>!OCMJ7QD^
M+>F:?\=/V9M?U6'QMJ7B3Q5J_CG5?'VJ^'OBKX!L?AQH!M8/$L=SX?O_  /'
M-9;+._>&, ^L?VAOBK^T9XY_:^\&_L;_ +.WQ*\+_ B>W_9M\5_M,^/OBUK_
M ,.+'XLZG?I#\0=*^%_P^^'F@>$]7US0=&L-.OM:N/$'B3QMKMQ-=:K+I>C:
M9H>@-H]WJESK5IU/[,O[:"?$;_@GWH_[9_QDTW2/"=QX7^&OQ4\3?%^S\/2S
M_P#"/6FM_ ;7/&WA+XDWGA@ZI-)>1:#J6M?#W7-2\-6VHW,U[!IE[86MY<3W
M22ROX_X@_9@_;OU7X@> ?VJM#^*O[*?A7]KG1OAGXW_9\\>Z=_PKCXL^(OV=
MO%OP5\1^.=&\>>%-1T[2;GX@:7\1-%^)G@#7M)N;ZVN6U^\\-^([?7M8T:^L
M["(V.HV>QXL_X)R"[_X)T>&?^"=_AGXESOX1U.?PAX?^-_C[7+&[T[7_ (C^
M =<^+-K\2_VE(-*L_#=];+X8UOXRPW_C?1K"*VOI;#PQ9^+I;>.>X6QAG8 ^
M2/A__P %!_VN6_86T_QI\8=,\%>"OVOO G[<O[)W[/\ \9= MO"\T>@6OP\_
M:;_:%^ U_P"''L?#>H7:W>G:A?\ [-GQZT#1AJDTSM!XVTO6-7@A<0+:CZ*_
M:U\2?MA^'OVV?V2_A%\)_P!J^#X<?#3]J?4/C997WAZ?X"?#7QIJ'@)/@M\'
MK?QU#)H'B+798[[4W\4ZS#<+J8UR"[6QM+LPZ8+<P1R-XW\4/^"/E_X9'QLL
M_P!CCQQX9^&WAKXKZO\ L3_%F+PC\:M;^,GQBL8OV@?V-/VBM(^*VE>*=6\1
M^(_'6L^-'\(>._AKHNC_  TUG1-.U^WN=/?P[H6H:7);P6[P5];Z5^S;^U%\
M2/C3^Q]\>_VC_&GP$B\8_LQ>+OVB[[4]%^"/AOXA:?X9\5^%?C%\)K/X>^&;
M>P;QYK^LZKI_B#0=4_M#4]>GN+B73;[3VLK?3[>WN4GD< ^.O%?[:_[6>C>&
M/C/^V59>./A^G[./P#_;?@_9.U+]G.X^&T5SXC\>?#7P]\>?"/[,OCOXKO\
M%F+7[?5=%^)U]X\\2ZGXX\)>';+0D\$V'A?1-/\ #>L66I:GJUUK5A^\5?CO
MXK_X)N_%_6]<^(_P9TWXU^ +3]AKXS?M3VO[7WQ%\"W_ ,/M<N_CY!XP?XI>
M%_C;XG^$/A3QW#XMM?!5I\+?&7Q7\*Q>)I]<OO",OC3P[I&L:QX2TR6ZMSI^
MKV'[$#ISP>XZXH **** "OP8^,O_  4G^._PG_;$_P""C'P'U*P\,P?#3X7_
M +,EGXD_93\;MH'G3Z5^TSHO[+?CG]H?7/ASXW(N_*\06GB_PGX=U#QMX12Y
M73]UO\//%^A1R7+SPM#^\]?CO^U!_P $L;O]I>U_X*31:A\3[#PKJG[9>A_
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MC#3O"-]XL\<> &U+0+36+;5-6TSPQK>F:Q>7EEJ-G';=C\1?V#OVHOB_\3?
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MKRI]E?LP_LC_ +0G@[XZ:5^T%^U#\6?A7\0?&'PX_9TC_98^%>E?!GX?>(_
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M]\/?C[^S)\'_ (=_L_\ [9'AS]DSP!^S]\=(/#WA2U_:*F\,Z#\+O$WQHO\
M4OC=X@\3V.L>&?'NIZ7\0O$1^$>@>#/#VH6=K/X'TQ?$VG>((?$E[/H^1^TG
M_P $=-5_:"^!7[3OP\7XN:-X4^(_Q;_;M\1?M@_"WX@66A:FT/@WPUXPL?A9
MX<\:_"3Q=:Q7T-]KNC>-?!W@G7M%\0BPN+>PGNM0\.:K]DEG\/Q(_2_M%_\
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MN+\Z9XT\!>.M&DCA\R%%_4[_ (*1_&?XI? 3]DWQ5\0?@SXBTSPE\1)/B+\
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MB#59/#^F>)=.T.\DO-1GM;F?24EMHH;5+6"$ ^WZ*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
8@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
